• Je něco špatně v tomto záznamu ?

Autoimmunity, cancer and COVID-19 abnormally activate wound healing pathways: critical role of inflammation

P. Gál, J. Brábek, M. Holub, M. Jakubek, A. Šedo, L. Lacina, K. Strnadová, P. Dubový, H. Hornychová, A. Ryška, K. Smetana

. 2022 ; 158 (5) : 415-434. [pub] 20220722

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22032909
E-zdroje Online Plný text

NLK ProQuest Central od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2000-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1997-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 1997-01-01 do Před 1 rokem

Odkazy

PubMed 35867145
DOI 10.1007/s00418-022-02140-x
Knihovny.cz E-zdroje

Recent evidence indicates that targeting IL-6 provides broad therapeutic approaches to several diseases. In patients with cancer, autoimmune diseases, severe respiratory infections [e.g. coronavirus disease 2019 (COVID-19)] and wound healing, IL-6 plays a critical role in modulating the systemic and local microenvironment. Elevated serum levels of IL-6 interfere with the systemic immune response and are associated with disease progression and prognosis. As already noted, monoclonal antibodies blocking either IL-6 or binding of IL-6 to receptors have been used/tested successfully in the treatment of rheumatoid arthritis, many cancer types, and COVID-19. Therefore, in the present review, we compare the impact of IL-6 and anti-IL-6 therapy to demonstrate common (pathological) features of the studied diseases such as formation of granulation tissue with the presence of myofibroblasts and deposition of new extracellular matrix. We also discuss abnormal activation of other wound-healing-related pathways that have been implicated in autoimmune disorders, cancer or COVID-19.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032909
003      
CZ-PrNML
005      
20240716101908.0
007      
ta
008      
230120s2022 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00418-022-02140-x $2 doi
035    __
$a (PubMed)35867145
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Gál, Peter, $u Department of Pharmacology, Pavol Jozef Šafárik University, Košice, Slovak Republic $u Department of Biomedical Research, East-Slovak Institute of Cardiovascular Diseases, Košice, Slovak Republic $u Prague Burn Centre, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic $d 1981- $7 xx0320027
245    10
$a Autoimmunity, cancer and COVID-19 abnormally activate wound healing pathways: critical role of inflammation / $c P. Gál, J. Brábek, M. Holub, M. Jakubek, A. Šedo, L. Lacina, K. Strnadová, P. Dubový, H. Hornychová, A. Ryška, K. Smetana
520    9_
$a Recent evidence indicates that targeting IL-6 provides broad therapeutic approaches to several diseases. In patients with cancer, autoimmune diseases, severe respiratory infections [e.g. coronavirus disease 2019 (COVID-19)] and wound healing, IL-6 plays a critical role in modulating the systemic and local microenvironment. Elevated serum levels of IL-6 interfere with the systemic immune response and are associated with disease progression and prognosis. As already noted, monoclonal antibodies blocking either IL-6 or binding of IL-6 to receptors have been used/tested successfully in the treatment of rheumatoid arthritis, many cancer types, and COVID-19. Therefore, in the present review, we compare the impact of IL-6 and anti-IL-6 therapy to demonstrate common (pathological) features of the studied diseases such as formation of granulation tissue with the presence of myofibroblasts and deposition of new extracellular matrix. We also discuss abnormal activation of other wound-healing-related pathways that have been implicated in autoimmune disorders, cancer or COVID-19.
650    _2
$a lidé $7 D006801
650    12
$a COVID-19 $7 D000086382
650    _2
$a autoimunita $7 D015551
650    _2
$a zánět $7 D007249
650    12
$a autoimunitní nemoci $x farmakoterapie $7 D001327
650    12
$a nádory $x farmakoterapie $7 D009369
650    _2
$a hojení ran $7 D014945
650    _2
$a nádorové mikroprostředí $7 D059016
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Brábek, Jan $u Department of Cell Biology, Faculty of Science, Charles University, 120 00, Prague 2, Czech Republic $u BIOCEV, Faculty of Science, Charles University, 252 50, Vestec, Czech Republic
700    1_
$a Holub, Michal $u Department of Infectious Diseases, First Faculty of Medicine, Military University Hospital Prague and Charles University, 160 00, Prague, Czech Republic
700    1_
$a Jakubek, Milan $u Department of Paediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University, 120 00, Prague 2, Czech Republic $u BIOCEV, First Faculty of Medicine, Charles University, 252 50, Vestec, Czech Republic $u Department of Analytical Chemistry, University of Chemistry and Technology Prague, 166 28, Prague 6, Czech Republic
700    1_
$a Šedo, Aleksi $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 120 00, Praha 2, Czech Republic
700    1_
$a Lacina, Lukáš $u BIOCEV, First Faculty of Medicine, Charles University, 252 50, Vestec, Czech Republic. lukas.lacina@lf1.cuni.cz $u Institute of Anatomy, First Faculty of Medicine, Charles University, 120 00, Prague 2, Czech Republic. lukas.lacina@lf1.cuni.cz $u Department of Dermatovenereology, First Faculty of Medicine, Charles University, 120 00, Prague 2, Czech Republic. lukas.lacina@lf1.cuni.cz
700    1_
$a Strnadová, Karolína $u BIOCEV, First Faculty of Medicine, Charles University, 252 50, Vestec, Czech Republic $u Institute of Anatomy, First Faculty of Medicine, Charles University, 120 00, Prague 2, Czech Republic
700    1_
$a Dubový, Petr $u Institute of Anatomy, Faculty of Medicine, Masaryk University, 625 00, Brno, Czech Republic
700    1_
$a Hornychová, Helena $u The Fingerland Department of Pathology, Faculty of Medicine Hradec Králové, Charles University, 500 05, Hradec Králové, Czech Republic
700    1_
$a Ryška, Aleš $u The Fingerland Department of Pathology, Faculty of Medicine Hradec Králové, Charles University, 500 05, Hradec Králové, Czech Republic
700    1_
$a Smetana, Karel $u BIOCEV, First Faculty of Medicine, Charles University, 252 50, Vestec, Czech Republic $u Institute of Anatomy, First Faculty of Medicine, Charles University, 120 00, Prague 2, Czech Republic
773    0_
$w MED00002042 $t Histochemistry and cell biology $x 1432-119X $g Roč. 158, č. 5 (2022), s. 415-434
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35867145 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20240716101905 $b ABA008
999    __
$a ok $b bmc $g 1891580 $s 1184244
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 158 $c 5 $d 415-434 $e 20220722 $i 1432-119X $m Histochemistry and cell biology $n Histochem Cell Biol $x MED00002042
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Možnosti archivace